Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
Polyrizon (PLRZ) has filed a divisional patent application in Israel for its Trap & Target (T&T) platform technology, focusing on advanced intranasal drug delivery systems. This follows their recent U.S. patent application covering both T&T and Capture and Contain (C&C) platforms.
The T&T platform aims to enhance medication effectiveness through improved nasal residence time and mucosal contact. Key features include prolonged residence time, improved bioavailability, controlled release, drip prevention, biodegradable components, and compatibility with various drug types including small molecules, proteins, peptides, and antibodies.
The technology leverages nasal cavity vascularization for both local and systemic drug delivery, targeting applications such as corticosteroids for allergic rhinitis, benzodiazepines for epileptic seizures, and naloxone for opioid overdose.
Polyrizon (PLRZ) ha presentato una domanda di brevetto divisional in Israele per la sua tecnologia di piattaforma Trap & Target (T&T), focalizzandosi su sistemi avanzati di somministrazione intranasale di farmaci. Questo segue la loro recente domanda di brevetto negli Stati Uniti che copre sia la piattaforma T&T che quella Capture and Contain (C&C).
La piattaforma T&T mira a migliorare l'efficacia dei farmaci attraverso un aumento del tempo di residenza nasale e del contatto con la mucosa. Le caratteristiche chiave includono un tempo di residenza prolungato, una bioavailability migliorata, un rilascio controllato, la prevenzione delle gocce, componenti biodegradabili e compatibilità con vari tipi di farmaci, tra cui piccole molecole, proteine, peptidi e anticorpi.
La tecnologia sfrutta la vascolarizzazione della cavità nasale per la somministrazione di farmaci sia locale che sistemica, puntando ad applicazioni come corticosteroidi per la rinite allergica, benzodiazepine per le crisi epilettiche e naloxone per il sovradosaggio da oppiacei.
Polyrizon (PLRZ) ha presentado una solicitud de patente divisional en Israel para su tecnología de plataforma Trap & Target (T&T), centrándose en sistemas avanzados de entrega de medicamentos intranasales. Esto sigue a su reciente solicitud de patente en EE. UU. que cubre tanto la plataforma T&T como la de Capture and Contain (C&C).
La plataforma T&T tiene como objetivo mejorar la efectividad de los medicamentos mediante un aumento del tiempo de residencia nasal y del contacto con la mucosa. Las características clave incluyen un tiempo de residencia prolongado, una mejor biodisponibilidad, liberación controlada, prevención de goteo, componentes biodegradables y compatibilidad con varios tipos de medicamentos, incluidos pequeñas moléculas, proteínas, péptidos y anticuerpos.
La tecnología aprovecha la vascularización de la cavidad nasal para la entrega de medicamentos tanto locales como sistémicos, dirigiéndose a aplicaciones como corticosteroides para la rinitis alérgica, benzodiazepinas para convulsiones epilépticas y naloxona para sobredosis de opioides.
Polyrizon (PLRZ)는 이스라엘에서 Trap & Target (T&T) 플랫폼 기술에 대한 분할 특허 출원을 하였으며, 고급 비강 약물 전달 시스템에 중점을 두고 있습니다. 이는 T&T 및 Capture and Contain (C&C) 플랫폼 모두를 포함하는 최근의 미국 특허 출원에 이어진 것입니다.
T&T 플랫폼은 비강 체류 시간과 점막 접촉을 개선하여 약물 효과를 강화하는 것을 목표로 합니다. 주요 특징으로는 연장된 체류 시간, 개선된 생체이용률, 조절된 방출, 물방울 방지, 생분해성 구성 요소 및 작은 분자, 단백질, 펩타이드 및 항체 등 다양한 약물 유형과의 호환성이 있습니다.
이 기술은 비강 혈관화를 활용하여 국소 및 전신 약물 전달이 가능하며, 알레르기 비염을 위한 코르티코스테로이드, 간질 발작을 위한 벤조디아제핀 및 오피오이드 과다복용을 위한 날록손과 같은 응용 프로그램을 목표로 하고 있습니다.
Polyrizon (PLRZ) a déposé une demande de brevet divisional en Israël pour sa technologie de plateforme Trap & Target (T&T), se concentrant sur des systèmes avancés de délivrance de médicaments intranasaux. Cela fait suite à leur récente demande de brevet aux États-Unis couvrant à la fois les plateformes T&T et Capture and Contain (C&C).
La plateforme T&T vise à améliorer l’efficacité des médicaments grâce à un temps de résidence nasal prolongé et un contact avec la muqueuse amélioré. Les caractéristiques clés incluent un temps de résidence prolongé, une biodisponibilité améliorée, un relâchement contrôlé, la prévention des gouttes, des composants biodégradables et une compatibilité avec divers types de médicaments, y compris les petites molécules, les protéines, les peptides et les anticorps.
La technologie exploite la vascularisation de la cavité nasale pour la délivrance de médicaments locaux et systémiques, ciblant des applications telles que les corticostéroïdes pour la rhinite allergique, les benzodiazépines pour les crises épileptiques et la naloxone pour les overdoses d'opioïdes.
Polyrizon (PLRZ) hat in Israel eine divisional Patentanmeldung für seine Trap & Target (T&T) Plattformtechnologie eingereicht, die sich auf fortschrittliche intranasale Arzneimittelabgabesysteme konzentriert. Dies folgt auf ihre kürzliche Patentanmeldung in den USA, die sowohl die T&T- als auch die Capture and Contain (C&C) Plattformen abdeckt.
Die T&T-Plattform zielt darauf ab, die Wirksamkeit von Medikamenten durch eine verbesserte nasale Verweildauer und Schleimhautkontakt zu erhöhen. Zu den wichtigsten Merkmalen gehören verlängerte Verweildauer, verbesserte Bioverfügbarkeit, kontrollierte Freisetzung, Tropfenverhinderung, biologisch abbaubare Komponenten und Verträglichkeit mit verschiedenen Arzneimitteltypen, einschließlich kleiner Moleküle, Proteine, Peptide und Antikörper.
Die Technologie nutzt die Vaskularisation der Nasenhöhle für die lokale und systemische Arzneimittelabgabe und zielt auf Anwendungen wie Kortikosteroide bei allergischer Rhinitis, Benzodiazepine bei epileptischen Anfällen und Naloxon bei einer Opioidüberdosis ab.
- Filed new divisional patent application strengthening intellectual property protection
- Platform technology compatible with wide range of drug types
- Technology addresses multiple therapeutic applications
- System designed to improve drug bioavailability and efficacy
- Company still in development stage with no commercialized products
Insights
The divisional patent application for Polyrizon's Trap & Target platform represents a strategic move to strengthen their IP position in the rapidly growing intranasal drug delivery market, currently valued at over
The platform's technical advantages are particularly noteworthy. The combination of prolonged residence time and improved bioavailability could significantly enhance the effectiveness of treatments for conditions like epileptic seizures and opioid overdose, where rapid drug absorption is crucial. The prevention of nasal dripping addresses a major limitation in current intranasal formulations, which typically have bioavailability rates of only
From a business perspective, this IP strategy creates multiple monetization opportunities:
- Potential licensing agreements with pharmaceutical companies seeking to reformulate existing drugs
- Development of proprietary drug products using the T&T platform
- Strategic partnerships for specific therapeutic applications
However, investors should note that the path to commercialization remains long and complex. The technology will require extensive validation through clinical trials and regulatory approval timelines could extend 3-5 years. The filing in Israel, while strategic for a company based there, will need to be followed by international patent applications to secure global market protection.
Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company’s advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company’s recently announced U.S. patent application which encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery.
The T&T platform represents a significant advancement in intranasal drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients (APIs) and addressing critical challenges in both local and systemic drug delivery. The divisional patent application underscores Polyrizon’s commitment to securing comprehensive intellectual property protection for its innovative technology, which aim to revolutionize respiratory health and drug delivery.
Key Potential Features of the Trap & Target (T&T) Platform:
| ● | Prolonged Residence Time: Enhancing the duration that drugs remain at the nasal absorption site, facilitating better absorption and efficacy. | |
| ● | Improved Bioavailability: , Increasing the amount of drug that reaches systemic circulation by bypassing first-pass metabolism and potentially improving therapeutic outcomes. | |
| ● | Controlled Release: Allows for precise management of API release kinetics to ensure optimal therapeutic levels over time. | |
| ● | Prevention of Dripping: The system is designed to prevent the formulation from dripping out of the nasal cavity to ensure maximum efficacy and patient comfort. | |
| ● | Biodegradable Components: Utilizing safe and environmentally friendly biodegradable polymers . | |
| ● | Versatility: Compatibility with a wide range of drug types, including small molecules, proteins, peptides, and antibodies, making it suitable for diverse therapeutic applications. |
Tomer Izraeli, CEO of Polyrizon, commented: “The filing of this divisional patent application for our Trap & Target platform marks another important step in strengthening our global intellectual property portfolio. We believe that the T&T platform has the potential to transform intranasal drug delivery by improving the efficacy and safety of a wide range of medications. We are committed to advancing this innovative technology to address critical healthcare challenges and improve patient outcomes.”
The T&T platform leverages the nasal cavity’s rich vascularization to facilitate both local and systemic drug delivery, offering a promising solution for various therapeutic applications, such as corticosteroids for allergic rhinitis, benzodiazepines for epileptic seizures and naloxone for opioid overdose. By enhancing drug absorption and bioavailability, the platform has the potential to improve the treatment of respiratory conditions, central nervous system disorders, and other medical needs.
This application aligns with the Company’s recently announced U.S. patent application which encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain (C&C™) and Trap and Target (T&T). The Capture and Contain (C&C™) platform utilizes a natural 3D polymeric network engineered to adhere optimally to the nasal mucosa. This advanced network forms a physical barrier that captures and contains airborne biological threats, such as allergens, viruses (such as Influenza), and molds, preventing their penetration and protecting the body.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its commitment to securing comprehensive intellectual property protection for its innovative technology, which aim to revolutionize respiratory health and drug delivery, its belief that the T&T platform has the potential to transform intranasal drug delivery by improving the efficacy and safety of a wide range of medications, its commitment to advancing this innovative technology to address critical healthcare challenges and improve patient outcomes and how the platform has the potential to improve the treatment of respiratory conditions, central nervous system disorders, and other medical needs. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s prospectus (Registration No. 333-266745), dated October 24, 2024 and filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
FAQ
What is the purpose of PLRZ's new Trap & Target patent application in Israel?
What are the key features of PLRZ's Trap & Target platform?
What therapeutic applications can PLRZ's T&T platform potentially address?
How does PLRZ's Trap & Target platform improve drug delivery?
